Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team.

Discover the major causes of partial paralysis from stroke and trauma to inflammatory conditions and tumors, plus warning ...